Clarivate posts Q2 revenue decline amid divestiture activity By Investing.com
Clarivate reported Q2 revenue of $587.3M, down 5.5% year over year and slightly below analysts’ $589.7M estimate, with adjusted EPS of $0.19 vs $0.18 consensus. The company cited revenue pressure from divestitures and lower transactional revenue. It kept 2026 revenue guidance at $2.3B to $2.42B and projected 2026 adjusted diluted EPS of $0.70 to $0.80.
How this was made
The 30-second read
Why it matters
Q2 shows revenue decline and net loss, with adjusted metrics mixed versus consensus; however, full-year revenue guidance and EPS outlook were maintained, reducing guidance-risk but not eliminating near-term earnings-quality concerns.
Market read
Traders can update expectations for near-term revenue trajectory and margin/EBITDA durability, while monitoring whether divestiture and subscription migration effects persist into subsequent quarters.
What to watch
The article notes product group wind-downs and customer migration to subscriptions; traders may need to assess whether these are temporary timing effects versus structural margin pressure.
Background
Clarivate is undergoing divestiture activity, including its Life Sciences and Healthcare business, while shifting revenue mix toward subscriptions.
Ticker impact
Clarivate (CLVT) reported Q2 revenue down 5.5% YoY to $587.3M, with adjusted EPS $0.19 and net loss $268.6M, citing divestitures and subscription migration.
Near-term downside bias versus expectations due to revenue and EBITDA miss, partially tempered by maintained 2026 revenue guidance and EPS range.
The article provides multiple earnings datapoints versus consensus (revenue and adjusted EBITDA below estimates, net loss reported) plus management guidance unchanged, which typically drives initial reaction and then re-focus on guidance credibility.
Market effects
Signals ongoing transition headwinds for data analytics/software firms with subscription mix shifts and portfolio divestitures.
KOSPI rebound and SK Hynix drop are mentioned but not causally linked to Clarivate.
Limited spillover beyond enterprise data analytics peers; focus remains on Clarivate’s divestiture-driven revenue dynamics.
Counterpoint
Investors may look through the inorganic divestiture drag and focus on maintained 2026 revenue guidance plus organic subscription growth of 0.7%.
Key entities
- companyClarivate
UK-based data analytics company reporting Q2 revenue decline, adjusted EPS beat, net loss, and maintained 2026 guidance amid divestitures.
